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Children with spinal muscular atrophy (SMA) types 2 and 3 are at risk for 
overweight and increased body fat. Research objectives were to determine whether 
increased caloric or fat intake were associated with weight increases across percentile 
curves over a 1 year period and to support alternative methodology for growth 
assessment. 
This retrospective, observational study used data collected at the University of 
Utah. Data were reviewed one visit prior to weight increases and at subsequent visits.   
Dietary data from type 2 (N=16) and type 3 (N=4) participants ages 0-18 years old were 
analyzed. Growth status assessment included only children with type 2 SMA (N=20). 
Assessments used weight-for-age percentiles, 3-day diet records and food 
analyses. Modified Hammersmith Functionality Scores and Compound Muscle Action 
Potential tracked disorder progression. Body fat percentages from dual energy x-ray 
absorptiometry (DXA) were compared to National Health and Nutrition Examination 
Survey (NHANES) percentile data and body mass index (BMI) percentiles on the Centers 
for Disease Control and Prevention (CDC) growth charts.  
Mixed-effect analysis was used to evaluate correlations between weight increases 
and both diet and disorder progression. Descriptive analysis was used to assess growth 







There was no statistical difference in dietary intake associated with weight increases. 
Disorder progression was not statistically different between visits. The majority of 
participants were obese with body fat percentages greater than the NHANES 95th 
percentile at the first and last visits (12 of 20 and 19 of 20, respectively). 
Results indicate that rapid weight gain in children with SMA is a product of 
disorder progression and not dietary alterations. Children with SMA may plot normally 
on the CDC BMI growth charts despite a high percent body fat. Alternative methodology 
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Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder 
resulting from a genetic mutation or deletion of the survival motor neuron (SMN) 1 gene 
on chromosome 5q13 (1, 2, 3). In a healthy population, the SMN1 gene and several 
copies of the SMN2 gene produce SMN protein, which is partially responsible for 
maintaining the function of motor neurons (4, 5). In persons with SMA, the mutation or 
deletion of SMN1 causes significantly reduced production of SMN protein, as the SMN2 
gene can only partially compensate for the lack of SMN1 (4). Ultimately, the 
homozygous mutation or deletion of SMN1 leads to degeneration of spinal motor 
neurons, progressive weakness and muscular atrophy (6, 7).   
The severity of SMA is generally associated with the number of SMN2 gene 
copies and subsequently how much SMN protein is produced in the body. Therefore, 
persons with less SMN protein tend to exhibit greater severity of symptoms (2, 8, 9). 
Clinically, classification of the disorder is based on age of onset and the maximum 
functional ability achieved by the individual (10, 11). Type 1, the most severe form of 
SMA, is characterized by age of onset prior to 6 months of age. These individuals never 
develop the ability to sit unassisted. Type 2 SMA manifests between 6 and 18 months of 
age. These individuals are able to sit unassisted at some point during their clinical course, 









and 10 years of age. Individuals with this form of the disorder can sit, stand, and walk 
unassisted at some point.  
Complications associated with SMA include, but are not limited to, diminished 
motor function, scoliosis, osteoporosis, pulmonary dysfunction, and feeding difficulties 
(7, 12, 13). Malnutrition, as evidenced by poor weight gain and decreased caloric intake, 
is most commonly seen in children with SMA type 1. This condition is of significant 
concern as weakened muscles may lead to dysphagia, fatigue during meals, difficulty 
chewing, and increased risk of choking (13, 14).  
Conversely, recent studies have shown that many children with SMA types 2 and 
3 may be at risk for excessive weight gain as evidenced by body fat percentage data 
consistent with overweight and obese (9, 15). In 2009, Sproule et al. used dual energy x-
ray absorptiometry (DXA) scans to determine fat mass and fat-free mass in children 
(n=25) with clinically diagnosed type 1, 2, or 3 SMA (15). Results showed statistically 
significant reductions in fat-free mass and increases in fat mass among children with 
SMA compared to healthy, age-matched peers. Many subjects who had a normal body 
mass index (BMI) plotted between the 85th and the 95th percentiles for percent body fat, 
which was consistent with the fat-mass index percentile cutoffs “at risk for overweight” 
and “overweight” at the time of the study. Research by Poruk et al. in 2012 on children 
with SMA type 1 (n=47) showed similar results (9). Fat mass was significantly increased 
and fat-free mass was significantly reduced in children with SMA when compared to 
healthy, age-matched peers. 
The research conducted by Sproule et al. and Poruk et al. indicates that there may 






condition. Conventional methods for classifying growth patterns in a healthy population, 
such as the CDC growth charts, do not accurately define growth in the SMA population 
(16, 17). Children with SMA who are diagnosed with failure to thrive based on CDC 
criteria may in fact be growing normally for their age and condition; however, children 
with SMA who appear to be growing normally on the CDC growth chart may have levels 
of excess fat mass similar to overweight and obese children in a healthy population (9). 
Increased fat mass consistent with overweight and obesity may negatively affect 
motor function in individuals with SMA (14). Muscle development is hindered in this 
disorder and progressive atrophy of these muscles makes them less equipped to carry 
excess fat. Decreased motor function and increased morbidity can result when the 
muscles of individuals with SMA are required to bear more weight (15). Excess fat mass 
is also associated with higher risk of metabolic syndrome, type II diabetes mellitus, and 
hypertension in children with SMA (15).   
Data gathered during routine clinical visits to the Clinical Neurosciences Center 
show an abnormal pattern of growth in children with types 2 and 3 SMA. At a point in 
their development, which varies by patient, the velocity of weight gain in these children 
increases dramatically; weight and BMI may jump one or two percentile curves on the 
CDC growth charts between visits. The objectives of this research were to determine 
whether diet alterations, such as increased caloric or fat intake, or the progressive course 
of the disorder were associated with abrupt weight increases across percentile curves in 
these children and to provide further evidence to support alternative methodology for 











In this retrospective, observational study participants were recruited between the 
years 2002 and 2014 as part of the natural history study “Clinical and Genetic Studies in 
SMA” at the University of Utah in Salt Lake City, Utah. Age of participants ranged from 
birth to 18 years. Parental consent was obtained for all subjects and assent was obtained 
in subjects older than 7 years. This study protocol was approved by the University of 
Utah Institutional Review Board for Human Subjects.  
Inclusion criteria for this study included a genetic confirmation of SMA 5q 
(SMN1 deletion or mutation) as well as clinical diagnosis of type 2 or 3 using medically 
sanctioned criteria. Children with type 1 SMA were not included in this study as they 
have shorter lifespans and typically do not experience abrupt increases in weight 
percentile.  
 
Data Collection Measures 
 
The data obtained for this study were gathered during routine clinical visits to the 
Clinical Neurosciences Center. Due to the wide range of ages and types of SMA subjects, 
the interval between their clinical visits varied, as did the length of time they chose to 
continue to be treated by the SMA clinical team. Therefore, the length of participation in 








up every 6 months, and type 3 patients’ follow up visits were typically every 6-12 
months. Participants were encouraged to continue with follow-up visits; however, they 
could discontinue their participation at any time.  
 
Dietary Intake 
To be included in this study, dietary documentation from at least two visits—one 
visit prior to the weight percentile increase and at least one subsequent visit until growth 
stabilized—had to be present. Dietary data were gathered for participants with type 2 
(N=16) and type 3 (N=4) SMA. Prior to each clinical visit, parents or participants, 
depending on the age of the participant, were given a 3-day dietary/supplement record to 
complete (Appendix A). Records were to include all food, fluid, and supplements 
consumed during 2 weekdays and 1 weekend day. Parents and participants were given 
written and verbal instructions on how to complete the record (1). All diet records were 
analyzed for total caloric and fat intake using ESHA Food Processor (version 10.5.2, 
2009 ESHA Research, Salem, Oregon). 
 
Anthropometrics 
Participants were weighed and measured during each clinical visit using 
standardized methods for SMA. Anthropometric measurements were completed by 
trained personnel. Weight was measured using an electronic scale and was documented to 
the nearest tenth of a kilogram. Scales used for measuring were calibrated, but the same 
scale was not consistently used between participants or clinical visits. Individuals who 






were unable to stand were measured in their wheelchairs (14). The weight of the 
wheelchair alone was measured and subtracted from the total weight of the participant. In 
order to be included in this study, participants had to exhibit an abrupt increase in weight, 
which was defined as an increase across one or more percentile curves on the CDC 
growth chart.  
Height was measured segmentally with a flexible measuring tape as many 
participants had significant contractures (18). Segments went from head to shoulder, 
shoulder to hip, hip to knee, knee to ankle, and ankle to heel. Height and weight were 
plotted on CDC growth charts to determine any changes in growth over time.   
 
Disorder Progression Data 
 Disorder progression was quantified using compound muscle action potential 
(CMAP) and Modified Hammersmith Functionality Scores (MHFS). CMAP is a measure 
of the action potential of muscle when exposed to an electrical stimulus. For the purposes 
of this study, CMAP amplitude, the maximum activity achieved by the muscle, and area, 
the total area under the action potential curve, were utilized. MHFS is a functional 
scoring system based on the ability to perform certain physical tasks such as the ability to 
sit unsupported. Disorder progression data were extracted from clinical visits for which 
dietary data were used.  
 
Dual Energy X-Ray Absorptiometry (DXA) 
Dual energy x-ray absorptiometry (DXA) scanning is a proven, reliable measure 






completed using Norland DXA (XR-36 software version 3.3.1, Fort Atkinson, 
Wisconsin) to evaluate body composition of participants with type 2 SMA (N=20) (18). 
Scans were obtained at least once per year; however, researchers could ask for additional 
DXA scans for research purposes. Submitting to these additional scans was optional.  
 
National Health and Nutrition Examination Survey (NHANES) Data 
Body fat percentages obtained via DXA scans were categorized using smoothed 
percentiles for body fat percentage from a 2011 NHANES Statistics Report (20). These 
percentiles were compared to corresponding BMI percentiles from CDC growth charts to 
determine whether children with type 2 SMA fall into similar percentile curves for body 
fat percentage and BMI.  
 
Demographics 
Parents and participants provided demographic information as part of their 
consent to participate in the natural history study, “Clinical and Genetic Studies in SMA” 
(1). Data used in this research included age, gender, ethnicity, and race.   
 
Statistical Methods, Data Analysis and Interpretation 
Data were collected and retrieved using REDCap (Research Electronic Data 
Capture) (19). The Statistical Analysis Software (version 9.1.2, 2010 SAS Institute Inc, 
Cary, North Carolina) was used to perform all data analyses (1). Mixed-effect analysis 
was employed to evaluate possible correlations between abrupt increases in weight and 






used to determine the consistency between definitions of overweight and obese based on 
body fat percentages from DXA scans and BMI percentiles on the CDC growth charts. 
The level of significance for statistical analyses was set at p<0.05. No power analysis was 








Demographic data for all participants are presented in Table 1. Age of participants 
ranged from birth to 18 years, with a mean age of 4.1 years. Female participants 
outnumbered males by two in both the SMA type 2 and the SMA types 2 and 3 groups. 
The majority of participants were Caucasian.   
Dietary data from 20 participants were collected for a total of 53 visits. The visits 
were generally 1 year apart. However, in order to increase the sample size, visits as far as 
2 years apart were included if the percentile jump was substantial. Route of intake for 
these children included full oral feeds (n=17), partial oral feeds with supplementary 
formula tube feeds (n=2), and full tube feeds (n=1). 
Changes in several dietary components, such as total caloric intake, total calories 
from fat, and fat distribution (percent calories from different fats) between visits was 
evaluated. Any change in diet was further compared to the increase in weight percentile 
to determine whether dietary modifications were correlated with weight gain. Due to 
large differences in caloric intake between participants with type 2 and type 3 SMA, an 
initial evaluation of the entire group (N=20) was compared to a second statistical analysis 
of participants with SMA type 2 alone (N=16). As shown in Tables 2 and 3, there was no 
significant change in any dietary component between visits, nor were dietary changes 








Disorder progression was quantified using CMAP and MHFS. Progression data 
were evaluated for the visit dates from which dietary data were extracted. Statistical 
analysis was completed to determine changes in disorder progression between visits and 
any change compared to the increase in weight percentile. Similar to dietary intake, there 
was no significant change in disorder progression measures between visits, nor were 
progression changes significantly related to an increase in weight percentile for the entire 
group or the type 2 group (see Tables 2 and 3).  
Descriptive data from the comparison of patient body fat percentages obtained via 
DXA scans to NHANES body fat percentiles are illustrated in Figure 1. This information 
was further compared to the number of children with type 2 SMA (N=20) within the 
given BMI-for-age percentiles on the CDC growth charts. As shown in Figure 1, the 
majority of children had a body fat percentage falling above the NHANES 95th percentile 
at their first and last clinical visits (12 of 20 and 19 of 20, respectively). Conversely, 
relatively few children had a BMI falling above the CDC growth chart 95th percentile at 
their first and last clinical visits (1 of 11 for both). Participants were also more evenly 
distributed among the lower CDC percentiles (<50th) than the NHANES percentiles. Nine 
participants were missing BMI data and were not included in the CDC BMI percentile 










Table 1. Subject demographic data of SMA type 2 and overall (type 2 and 3) 
  SMA Type 2 
(N=16) 
SMA Type 2 and 
3 (N=20) 
 
Age (yrs) Mean (Std) 4.1 (2.0) 4.1 (2.4) 
 Median (IQR) 4.1 (2.3-5.7) 3.5 (2.1-5.7) 
  N (%) N (%) 
Gender Male  7 (43.8) 9 (45) 
 Female 9 (56.3) 11 (55) 
Ethnicity  Hispanic or Latino 2 (12.5) 2 (10) 
 Not Hispanic or Latino 14 (87.5) 17 (85) 
 Not Reported 0 (0) 1 (5) 
Race Caucasian 15 (93.8) 18 (90) 









Table 2. Relationship of nutrition intake and disorder progression versus percentile increase in type 2 SMA (N=16)  
  Difference between visits Difference compared to 
percentile increase 
Intake/Disorder Progression Variable Mean 
 




P-value Mean difference + 
standard error 
P-value 
Total caloric intake (kcal) 1078.6 27.31 + 55.32 0.63 0.01 + 0.01 0.37 
Calories from fat (kcal) 338.9 21.49 + 29.82 0.48 0.00 + 0.02 0.84 
Calories from saturated fat (kcal) 117.0 4.84 + 10.70 0.66 -0.02 + 0.04 0.72 
Saturated fat distribution (% calories) 13.0 0.54 + 1.19 0.66 -0.14 + 0.37 0.72 
Monounsaturated fat distribution (% calories) 9.5 0.51 + 1.09 0.6 0.67 + 0.43 0.16 
Polyunsaturated fat distribution (% calories) 4.6 0.12 + 0.59 0.85 1.10 + 0.69 0.16 
Trans fatty acid distribution (% calories) 0.4 0.19 + 0.14 0.20 -6.55 + 3.47 0.12 
Compound Muscle Action Potential AM (mV) 2.68 0.15 + 0.21 0.46 -0.93 + 2.39 0.71 
Compound Muscle Action Potential Area (mV) 6.13 0.11 + 0.50 0.83 0.70 + 1.01 0.51 










Table 3.  Relationship of nutrition intake and disorder progression versus percentile increase in type 2 and type 3 SMA (N=20) 
  Difference between visits Difference compared to 
percentile increase 
Intake/Disorder Progression Variable Mean 
 




P-value Mean difference + 
standard error 
P-value 
Total caloric intake (kcal) 1099.55 -3.33 + 52.97 0.95 0.01 + 0.01 0.32 
Calories from fat (kcal) 352.15 13.78 + 24.30 0.58 0.00 + 0.01 0.96 
Calories from saturated fat (kcal) 120.79 2.09 + 9.00 0.82 -0.01 + 0.03 0.84 
Saturated fat distribution (% calories) 13.39 0.27 + 1.00 0.79 -0.07 + 0.31 0.83 
Monounsaturated fat distribution (% calories) 11.02 0.58 + 1.43 0.69 0.20 + 0.20 0.37 
Polyunsaturated fat distribution (% calories) 4.85 0.22 + 0.55 0.69 0.98 + 0.60 0.15 
Trans fatty acid distribution (% calories) 0.49 0.11 + 0.11 0.32 -4.87 + 3.23 0.18 
Compound Muscle Action Potential AM (mV) 3.28 0.11 + 0.20 0.58 -1.07 + 2.01 0.61 
Compound Muscle Action Potential Area (mV) 7.64 0.22 + 0.44 0.63 0.72 + 0.91 0.45 











Figure 1. Distribution of participant body fat percentage (BF%) according to the 
NHANES percentiles compared to participant BMI according to the CDC percentiles in 




















































Children with type 2 and type 3 SMA may be at risk for overweight and obesity 
as evidenced by increased body fat and decreased lean body mass (15). Our study 
participants have demonstrated a unique growth behavior; weight may steadily follow a 
percentile curve for some time and then abruptly rise across percentile curves without a 
significant increase in caloric intake. This rapid weight increase is a cause for concern as 
it may speed future disorder progression and limit mobility. Furthermore, the weight gain 
may lead to comorbidities such as metabolic syndrome (14, 15).  
This research indicates that sudden increases in weight seen in children with SMA 
types 2 and 3 are not likely related to alterations in caloric or fat intake. Total caloric 
intake did not significantly differ between visits for either the entire group or the SMA 
type 2 group. Similarly, calories from fat and fat distribution were not statistically 
different between visits for either group. Therefore, weight gain does not seem to be a 
product of energy input variations. We hypothesize that weight gain may rather be related 
to diminishing energy output over time.  
Although this study did not find any significant changes in disorder progression 
scores between visits, SMA and disorder progression may have some association with 
increased weight gain. Visits were generally no more than a year apart, which may not be 







Research by Swoboda et al. and Kaufmann et al. found that children with SMA types 2 
and 3 did not show any changes in motor function after 12 months (21, 22).   
Many children with SMA, especially individuals with type 2 and type 3, develop 
overweight and obesity according to body fat percentage (23, 24, 25). The cause of 
weight gain is likely multifactorial. Children with SMA have lower calorie needs (intake 
requirements are typically 7-14 kcal/cm height, which equates to roughly 60-80% of the 
RDA) than their healthy age-matched peers due to decreased energy output (25). Lean 
body tissue is progressively degenerated as a result of SMA. As muscle is lost, the body 
becomes less metabolically active and energy output decreases. Furthermore, as SMA 
progresses and muscle is lost, the ability to perform physical activity decreases. Both 
factors lead to diminishing energy output and decreasing caloric requirements over time. 
Thus, patients with SMA types 2 and 3 who do not alter their intake as output decreases 
will gain excess fat.  
Recent studies with SMN-depleted mice, children with Duchenne muscular 
dystrophy (DMD), and children with spinal cord injuries (SCI) support this multifactorial 
process of weight gain. SMN-depleted mice are a useful model for the less severe forms 
of SMA such as type 2 and type 3 (26). Bowerman et al. found that SMN-depleted mice 
were generally 15-20% heavier than control mice, which researchers attributed to 
metabolic dyshomeostasis. DMD is a neuromuscular disorder that causes muscle 
weakness and atrophy similar to SMA (27). In a study from 2005, young boys with DMD 
had lower resting energy expenditures (REE) than their healthy age-matched peers (28). 
Leroy-Willig et al. also showed that higher fat mass and lower lean body mass than that 






develop muscular dysfunction, which causes deficits in lean muscle mass and decreased 
physical activity (30). A study in 2006 showed that children with SCI had significantly 
lower lean muscle mass and REEs that were, on average, 15.5% lower than healthy 
controls. Researchers hypothesized that decreased metabolic and physical activity due to 
muscle loss were the likely causes of body composition changes in children with DMD 
and SCI (27, 30).  
These findings support the results of the current research. Namely, that weight 
gain in children with SMA is likely a result of decreased calorie needs due to lower 
metabolic and physical activity (disorder progression) rather than alterations in diet. 
Treatment of overweight and obesity requires a very delicate balance. Although excess 
fat mass increases disease morbidity and risk of diabetes and cardiac dysfunction, 
aggressive weight loss is not an effective solution. Calorie restriction may cause muscle 
breakdown, which is not easily regenerated (14, 15, 27). Similarly, negative nitrogen 
balance from inadequate protein intake can speed the process of muscular atrophy. 
Preventing overweight and obesity is likely the best treatment. However, treatment for 
children with SMA who already suffer from overweight or obesity should include an 
individualized plan that promotes gradual weight loss or continued growth along their 
established growth curve (23).  
Descriptive data from Table 4 indicate that children with type 2 SMA who are 
categorized as overweight or obese based on body fat percentage may not be similarly 
categorized when using BMI and CDC growth charts. Research from children with DMD 
and SCI indicate that BMI is not an accurate indicator of growth status. In a study from 






for zero muscle mass (ZMM) (31). ZMM is an equation that uses creatinine excretion to 
estimate lean body mass, which is then subtracted from the participant’s total weight to 
estimate fat mass. Five participants were classified as overweight according to BMI 
compared to 30 participants according to ZMM, suggesting that BMI is not an accurate 
measurement in this population.  
Research from the SCI population shows similar findings. In the study conducted 
by Liusuwan et al., participants with SCI had a similar BMI to the healthy controls 
despite having a significantly higher percent body fat (30). BMI is not a sensitive 
indicator of body composition and growth, as it does not distinguish between fat mass 
and fat-free mass. Researchers have seen statistically significant reductions in fat-free 
mass and increases in fat mass among children with SMA type 2 and 3 compared to 
healthy, age-matched peers (15). As indicated by the current study and previous research, 
BMI is not an effective measurement of growth status and cannot be used to diagnose 
overweight and obesity in children with SMA.  
 
Limitations 
A limitation of this study is the small sample size. Many children with SMA types 
2 and 3 showed the pattern of weight gain described in this study but lacked dietary or 
disorder progression data for the visit dates in which the weight gain was seen. 
Additionally, some study candidates showed an increase in weight but it manifested 
between visit dates that were too many years apart. The conclusions of this research are 






Potential error in dietary documentation and anthropometric measurements is a 
second limitation of this study. Three-day diet records were completed by parents or the 
participants rather than a dietitian or other member of the SMA clinical team. Parents and 
participants may document intake with a low level of specificity, which makes accurate 
dietary analysis difficult. Similarly, there was potential for error in anthropometric 
measurements. In particular, accurate measurements of height may be difficult to obtain 
if the child has contractures. The scales used to measure weight varied between patient 
and clinical visit, which possibly decreased the accuracy of this measure.  
The use of descriptive statistics when comparing NHANES body fat percentiles to 
BMI percentiles on the CDC growth chart is another limitation. Although this 
information is useful, it lacks statistical power. The NHANES Statistical Report from 
2011 also used a GE Holistic DXA machine, whereas researchers in this study used a 
Norland DXA machine. The use of different machines may cause discrepancies between 
the body fat percentages used to create the NHANES percentiles and the body fat 
percentages obtained for the participants of this study.  
 
Conclusion 
Our study results support current knowledge of overweight and obesity in 
children with SMA and neuromuscular conditions. The development of excess fat mass 
in children with SMA type 2 and type 3 is most likely secondary to the progressive nature 
of SMA rather than alterations in caloric or fat intake. Research to determine the causes 
of these sudden increases in weight across percentile curves is necessary. This 






preventing the development of overweight and obesity. Also, established guidelines for 
nutrition management in people with SMA who already suffer from excess fat are 
essential as aggressive weight-loss measures can result in further muscle loss. Small, 
incremental decreases in calories may be beneficial. Finally, this study adds support for 













APPENDIX: FOOD RECORD 
 
FOOD RECORD 
Child’s name: ________________________________________________________  
Name of the caregiver(s) completing this form: 
__________________________________________  










My child’s feeds are:  
___All by mouth  
___By mouth and by feeding tube  
___Restricted to feeding tube only 
  
Please return this form to:  
 
Dr. Kathryn Swoboda  
Pediatric Motor Disorders Research Program  
Department of Neurology  
University of Utah School of Medicine:  
50 North Medical Drive, Room 3R210  
Salt Lake City, Utah 84132  
FAX: 801-587-9346  
 




Nutritional Care Guidelines for children with SMA and other neuromuscular disorders are 







DIRECTIONS FOR KEEPING THIS FOOD 
DIARY: 
 
Please record everything your child eats or drinks over a three day period, preferably two 
weekdays and one weekend day. This record should include feeds and supplements and all water 
or other liquids given via mouth, nasogastric, nasojejunal or gastrostomy tube. If your child 
consumes the identical diet each day via tube-feeding, just indicate this, and completion of only a 
single day is necessary.  
 
1. Record all food and drink whether eaten/given at home or away from home. 
  
2. Be as specific as possible in recording the item, and use a brand name if available and include a 
label for nutrient information.  
 
3. Measure the item when possible or estimate the amount using the pictures provided with this 
document. You can record in cubic centimeters (cc) or ounces (oz) with regard to liquids, and 
either ounces (oz) or grams (g) for food items.  
 
4. Please mention if possible how the food was prepared (fried, boiled, baked, microwaved, etc) 
and record items used in the preparation, including oil, margarine or butter, for instance.  
 
5. Don’t forget to include all condiments, such as catsup, gravy, sauce, butter or oil, and record 
amounts as accurately as possible. For instance, you might record 2 french fries with 1 teaspoon 
catsup. 
  
6. Please include one item per line where possible. 
  
7. Please include all supplements (vitamins) given, with brand names and labels if possible.  
 
8. You can use abbreviations for measurements:  
Teaspoon – tsp  ¼ cup – ¼ C  
Tablespoon – Tbsp  Ounce – oz  
 
9. For infants, record the duration and frequency of breast feeds, as well as the pre- and post-
feeding weight of your infant one time per day.  
 
EXAMPLE: INFANT’S DIET  
Try to record only what is eaten (and not what falls in the lap or on the floor) 
  
Dinner:  1 x 4 oz jar stage I pears (Gerber)  
6 ounces Carnation Goodstart Formula  
 
EXAMPLE: INFANT’S DIET, GASTROSTOMY TUBE WITH BOLUS FEEDING 
  
Lunch   1 x 4 oz jar stage I peaches (1 Tbsp by mouth, the rest via G-tube)  
6 oz formula (Pediatric Vivonex Standard dilution for 20 calories/oz)  
 






EXAMPLE: INFANT’S DIET: GASTROSTOMY TUBE ONLY, CONTINUOUS FEEDS 
  
Continuous feeds: 45 cc/hour, pediatric Vivonex standard dilution  
OR  
Continuous feeds: 45 cc/hour, Tolerex formula with added nutrients including the following. 
. .  
Total recipe = (please include all ingredients including added vitamins, oil, juices and any 
supplements)  
 
EXAMPLE: TODDLER’S DIET  
Try to record only what is actually eaten  
 
Dinner: 2 Tbsp stage II squash (Gerber)  
½ C whole milk  
1 oz chicken (2 pieces of chicken tenders, brand name, baked)  
5 small pieces of cantaloupe (grape sized)  
¼ cup macaroni and cheese (Annie’s brand, prepared as directed)  
 
 









PLEASE CIRCLE DAYS RECORDED AND DATES 
  
SUN MON TUES WED THURS FRI SAT  
DATE(S):_______________________  
 















FOR ADDITIONAL VITAMIN, MINERAL OR HERBAL SUPPLEMENTS OF ANY 
TYPE, INCLUDING PROTEIN OR AMINO ACID SUPPLEMENTS: please list brand 















BREASTFEEDING: please list approximate time and duration of feeding in the table below. 
If you think you can estimate how much your baby receives in terms of ounces or cc’s, please 
do so. If you pump breastmilk, this can provide some estimate of how much your baby might 
be getting per feed. If your baby feeds frequently for short periods of time, estimate total 
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